Abstract
Background: In the pivotal OAK study, the 2/3L treatment for advanced or metastatic NSCLC with atezolizumab (atezo) resulted in improvement of OS. Despite its efficacy has been approved, little is known about atezo clinical outcomes in routine practice in the Asian population. This study aimed to understand the clinical characteristics and outcomes of NSCLC patients treated with atezo in second-line and beyond (2L+) in the real-world setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
